Cerebrospinal Fluid Hemoglobin to Monitor for Aneurysmal Subarachnoid Hemorrhage Related Secondary Brain Injury
NCT04998370
Brain Diseases, Cardiovascular Diseases
Linz, Austria
View Trial DetailsNCT Number: NCT03361722
Vasospasm is a current complication after aneurysmal subarachnoid hemorrhage and often and often associated with brain ischemia. This complication is difficult to detect, because clinical examination is hardly helpful in sedated patients and the performances of transcranial doppler can only detect the spasm of middle cerebral arteries.
Tissue Oxygen Pressure (PtiO2) Monitoring allows early detection of brain oxygenation local modifications and of brain ischemia, via continuous monitoring.
This study aims to assess the performance of the tissue oxygen pressure monitoring in detecting a vasospasm post aneurysmal subarachnoid hemorrhage.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: O2-VASO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04998370
Brain Diseases, Cardiovascular Diseases
Linz, Austria
View Trial DetailsNCT07196891
Brain Diseases, Cardiovascular Diseases
Istanbul, Fatih, Turkey (Türkiye)
View Trial DetailsNCT07052656
Acute Brain Injuries, Acute Neurological Injury
Stockholm, Sweden
View Trial DetailsNCT03309579
Brain Diseases, Cardiovascular Diseases
Aurora, Colorado, United States
View Trial Details